Therapy News and Research

RSS

Research reveals effectiveness of carvedilol in preventing variceal hemorrhage

Patients with cirrhosis are at risk for developing portal hypertension that can lead to the formation, dilation, and rupture of esophageal varices. The annual incidence of esophageal varices is approximately 5% and one third of those will bleed.

20 Aug 2009

Study unveils detrimental effects of high-dose ursodeoxycholic acid on patients with PSC

Primary sclerosing cholangitis (PSC) is an uncommon chronic liver disease characterized by progressive inflammation and destruction of the bile ducts. The disease progresses slowly, usually leading to biliary cirrhosis, portal hypertension and liver failure over a 10-15 year period. PSC is a common cause of adult cholestatic liver diseases and a primary source behind many of the liver transplantations in U.S. adults. At least 70% of PSC cases are associated with chronic inflammatory bowel disease (IBD), usually ulcerative colitis. Currently, there is no cure for PSC and prospective treatments remain ineffective.

20 Aug 2009

Diarrhea remains second leading cause of death among children, despite effective interventions

Despite the introduction of new treatments for diarrhea more than four years ago, few children in developing countries are receiving these interventions and the disease is still the second leading cause of death among children, according a Bulletin of the World Health Organization report, BMJ reports.

20 Aug 2009

Aton Pharma markets preservative-free drugs for glaucoma

Aton Pharma, Inc., a diversified specialty pharmaceutical company, today announced it has launched new education, distribution, sampling and reimbursement programs for TIMOPTIC(R) in OCUDOSE(R), the only preservative-free medication for glaucoma available in the United States. Aton acquired the U.S. marketing rights in February to the TIMOPTIC product line from Merck & Co., Inc. TIMOPTIC (timolol maleate) is a non-selective beta-adrenergic receptor blocking agent indicated for the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. As many as 2.25 million Americans suffer from open-angle glaucoma.

20 Aug 2009

InterMune receives $20 million event payment from Roche for initiating the Phase 2b trial of RG7227/ ITMN-191

Roche (SIX: ROG.VX; RO.S, OTCQX: RHHBY) and InterMune, Inc. (Nasdaq: ITMN) today announced that the first patient has been dosed in a Phase 2b study evaluating the hepatitis C virus (HCV) protease inhibitor, RG7227/ ITMN-191, in combination with PEGASYS(R) (pegylated interferon alfa-2a) and COPEGUS(R) (ribavirin). The study, to be conducted at 45 sites globally, will further define the safety and efficacy profile of RG7227/ ITMN-191, for a treatment duration of up to 24 weeks. Approximately 300 treatment-naive patients chronically infected with HCV genotype 1 - the most difficult to treat form of the virus - will participate.

20 Aug 2009

First-quarter fiscal 2010 results announced by Cyberonics

Cyberonics, Inc. today announced results for the quarter ended July 24, 2009. Net sales were $38.5 million, a 14% increase from $33.7 million in the first quarter of fiscal 2009.

20 Aug 2009

Scientists develop new technique to target brain cancer cells

Scientists from the U.S. Department of Energy's (DOE) Argonne National Laboratory and the University of Chicago's Brain Tumor Center have developed a way to target brain cancer cells using inorganic titanium dioxide nanoparticles bonded to soft biological material.

20 Aug 2009

Anthem Media Group acquires Ascend Media's Allied Healthcare division

Anthem Media Group (AMG) announced today its acquisition of Ascend Media's Los Angeles-based medical media division for an undisclosed sum. The news comes just days after Inc. Magazine named the Kansas City-based Anthem one of the nation's fastest-growing companies.

20 Aug 2009

DNA-encased carbon nanotubes used for treating human prostate cancer tumors in mice

Researchers at Wake Forest University School of Medicine have destroyed prostate cancer tumors in mice by injecting them with specially-coated, miniscule carbon tubes and then superheating the tubes with a brief zap of a laser.

20 Aug 2009

African Americans receive less mental illness treatments and diagnoses than Caucasian Americans

According to the Surgeon General, only one-third of Americans with a mental health problem seek treatment; the percentage of African Americans getting help is only half that of non-Hispanic whites.

19 Aug 2009

Steroid hormones found to affect gene activity

Intermittent signaling by steroid hormones can affect the way genes are expressed in rodents, according to research by scientists at the University of Bristol and the National Cancer Institute (NCI), USA. This work has major implications for understanding how steroids work and opens novel avenues for new therapies.

19 Aug 2009

Nano-bio material kills cancer cells, leaves healthy cells in unharmed

19 Aug 2009

Nurses and clinical officers in Africa know when a person should receive antiretroviral therapy

Nurses and clinical officers (non-physician clinicians, NPCs) are capable of determining when a person should receive antiretroviral therapy (ART) for HIV/AIDS. Researchers writing in BioMed Central's open access journal Human Resources for Health suggest that this should ease the strain on overstretched doctors in sub-Saharan Africa and thereby help increase access to antiretroviral therapy, particularly in rural areas.

19 Aug 2009

Newly discovered anti-aging gene linked to high blood pressure

Researchers at the University of Oklahoma Health Sciences Center have shown the first link between a newly discovered anti-aging gene and high blood pressure. The results, which appear this month in the journal Hypertension, offer new clues on how we age and how we might live longer.

19 Aug 2009

U.S. FDA approval of miconazole MBT represents a significant milestone for Strativa Pharmaceuticals

Strativa Pharmaceuticals, the proprietary products division of a wholly owned subsidiary of Par Pharmaceutical Companies, Inc. (NYSE: PRX), today announced that the U.S. Food and Drug Administration (FDA) has accepted the new drug application (NDA) for miconazole Lauriad((R)) mucoadhesive buccal tablets (MBT) to treat oropharyngeal candidiasis (OPC).

19 Aug 2009

Health Research International publishes reports on opportunities presented by transcatheter and minimally invasive surgical valve technologies

Transcatheter heart valve technologies are positioned to become the next disruptive influence in cardiovascular medicine and drive a multi-billion dollar market. However, questions remain about the timing of adoption of these new technologies, the numbers and types of patients ultimately benefitting from them, the impact of reimbursement, and where transcatheter technologies pose the greatest threat to the current surgical caseload, especially in light of developments in minimally invasive heart valve surgery technologies.

19 Aug 2009

Light Sciences Oncology announces Phase 2 trial of Aptocine in Benign Prostatic Hyperplasia

Light Sciences Oncology, Inc. (LSO) today announced the treatment of the first patients in a Phase 2 clinical trial of its innovative targeted drug treatment Aptocine(TM) (talaporfin sodium) in Benign Prostatic Hyperplasia (BPH). The Phase 2 trial expands the Aptocine BPH development program on the basis of a Phase 1 study at escalating light doses. In the open-label Phase 2 trial, Aptocine is being tested for safety and efficacy in 40 patients with lower urinary tract symptoms (LUTS) due to BPH. Aptocine is also in two Phase 3 clinical trials for solid tumors in the liver as well as preclinical development for prostate cancer.

19 Aug 2009

Researchers find connection between eye disease and arginase

Elevated levels of the enzyme arginase contribute to vascular eye damage and Medical College of Georgia researchers say therapies to normalize its levels could halt progression of potentially blinding diseases such as diabetic retinopathy.

19 Aug 2009

Gentium reports results from phase 3 trial of defibrotide for severe veno-occlusive disease

Gentium S.p.A. has announced top-line results from a historically controlled, multicenter, open label, Phase III trial designed to evaluate the safety and efficacy of 25 mg/kg/day of Defibrotide for the treatment of severe veno-occlusive disease (sVOD) in hematopoietic stem cell transplant (SCT) patients.

19 Aug 2009

The Parkinson's Disease Foundation and the Davis Phinney Foundation jointly fund new study

The Davis Phinney Foundation, a non-profit organization dedicated to improving the lives of people with Parkinson's disease (PD) today, announced that it has awarded four Parkinson's disease research centers with support to conduct a landmark study on the long-term changes in quality of life and mobility that occur in people with PD. The results of this research will help to advance the understanding of how interventions, such as exercise, impact changes in quality of life and mobility over the course of the disease.

19 Aug 2009

Therapy News and Research

Research reveals effectiveness of carvedilol in preventing variceal hemorrhage

Study unveils detrimental effects of high-dose ursodeoxycholic acid on patients with PSC

Diarrhea remains second leading cause of death among children, despite effective interventions

Aton Pharma markets preservative-free drugs for glaucoma

InterMune receives $20 million event payment from Roche for initiating the Phase 2b trial of RG7227/ ITMN-191

First-quarter fiscal 2010 results announced by Cyberonics

Scientists develop new technique to target brain cancer cells

Anthem Media Group acquires Ascend Media's Allied Healthcare division

DNA-encased carbon nanotubes used for treating human prostate cancer tumors in mice

African Americans receive less mental illness treatments and diagnoses than Caucasian Americans

Steroid hormones found to affect gene activity

Nano-bio material kills cancer cells, leaves healthy cells in unharmed

Nurses and clinical officers in Africa know when a person should receive antiretroviral therapy

Newly discovered anti-aging gene linked to high blood pressure

U.S. FDA approval of miconazole MBT represents a significant milestone for Strativa Pharmaceuticals

Health Research International publishes reports on opportunities presented by transcatheter and minimally invasive surgical valve technologies

Light Sciences Oncology announces Phase 2 trial of Aptocine in Benign Prostatic Hyperplasia

Researchers find connection between eye disease and arginase

Gentium reports results from phase 3 trial of defibrotide for severe veno-occlusive disease

The Parkinson's Disease Foundation and the Davis Phinney Foundation jointly fund new study

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

Latest News